Yusuke Moritoh

Fujisawa, 2518555, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

First clinical demonstration of sustained insulin-like growth factor 1 elevation via oral somatostatin receptor 5 antagonism: a phase 1 trial of SCO-240.

First clinical demonstration of sustained insulin-like growth factor 1 elevation via oral somatostatin receptor 5 antagonism: a phase 1 trial of SCO-240.

Journal: European journal of endocrinology
Published: April 07, 2026

Oral SSTR5 Antagonist SCO-240 for Growth Hormone Stimulation: A Phase I Single-Dose Study in Healthy Individuals.

Oral SSTR5 Antagonist SCO-240 for Growth Hormone Stimulation: A Phase I Single-Dose Study in Healthy Individuals.

Journal: Clinical pharmacology and therapeutics
Published: September 20, 2023

An Exploratory Randomized Trial of SCO-792, an Enteropeptidase Inhibitor, in Patients With Type 2 Diabetes and Albuminuria.

An Exploratory Randomized Trial of SCO-792, an Enteropeptidase Inhibitor, in Patients With Type 2 Diabetes and Albuminuria.

Journal: Kidney international reports
Published: May 31, 2022

Liquid chromatography-mass spectrometry measurements of blood diphosphoinositol pentakisphosphate levels.

Liquid chromatography-mass spectrometry measurements of blood diphosphoinositol pentakisphosphate levels.

Journal: Journal of chromatography. A
Published: May 12, 2022

Erratum. SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans. Diabetes 2021;70:2364-2376.

Erratum. SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans. Diabetes 2021;70:2364-2376.

Journal: Diabetes
Published: December 27, 2021

Erratum. SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans. Diabetes 2021;70:2364-2376.

Erratum. SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans. Diabetes 2021;70:2364-2376.

Journal: Diabetes
Published: October 30, 2021

Dichloroacetate, a pyruvate dehydrogenase kinase inhibitor, ameliorates type 2 diabetes via reduced gluconeogenesis.

Dichloroacetate, a pyruvate dehydrogenase kinase inhibitor, ameliorates type 2 diabetes via reduced gluconeogenesis.

Journal: Heliyon
Published: August 16, 2021

SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans.

SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans.

Journal: Diabetes
Published: May 21, 2021

The enzymatic activity of inositol hexakisphosphate kinase controls circulating phosphate in mammals.

The enzymatic activity of inositol hexakisphosphate kinase controls circulating phosphate in mammals.

Journal: Nature communications
Published: November 11, 2020

Enteropeptidase inhibition improves obesity by modulating gut microbiota composition and enterobacterial metabolites in diet-induced obese mice.

Enteropeptidase inhibition improves obesity by modulating gut microbiota composition and enterobacterial metabolites in diet-induced obese mice.

Journal: Pharmacological research
Published: September 20, 2020

Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats.

Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats.

Journal: Molecular pharmacology
Published: September 17, 2020

Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety.

Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety.

Journal: Journal of medicinal chemistry
Published: September 09, 2020
Showing 1-12 of 20

Last Updated: 09/26/2026